NASDAQ:ANAB AnaptysBio (ANAB) Stock Price, News & Analysis $20.14 -0.28 (-1.37%) As of 11:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AnaptysBio Stock (NASDAQ:ANAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AnaptysBio alerts:Sign Up Key Stats Today's Range$19.57▼$20.4250-Day Range$14.64▼$21.5852-Week Range$12.21▼$41.31Volume167,987 shsAverage Volume595,401 shsMarket Capitalization$617.63 millionP/E RatioN/ADividend YieldN/APrice Target$33.63Consensus RatingModerate Buy Company OverviewAnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Read More… AnaptysBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreANAB MarketRank™: AnaptysBio scored higher than 49% of companies evaluated by MarketBeat, and ranked 546th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAnaptysBio has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AnaptysBio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AnaptysBio are expected to grow in the coming year, from ($6.08) to ($5.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AnaptysBio is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AnaptysBio is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnaptysBio has a P/B Ratio of 6.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AnaptysBio's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted53.19% of the float of AnaptysBio has been sold short.Short Interest Ratio / Days to CoverAnaptysBio has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in AnaptysBio has recently increased by 9.49%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnaptysBio does not currently pay a dividend.Dividend GrowthAnaptysBio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted53.19% of the float of AnaptysBio has been sold short.Short Interest Ratio / Days to CoverAnaptysBio has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in AnaptysBio has recently increased by 9.49%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment1.07 News SentimentAnaptysBio has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for AnaptysBio this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for ANAB on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows2 people have added AnaptysBio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AnaptysBio insiders have not sold or bought any company stock.Percentage Held by Insiders33.70% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about AnaptysBio's insider trading history. Receive ANAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter. Email Address ANAB Stock News HeadlinesWells Fargo Sticks to Their Buy Rating for AnaptysBio (ANAB)April 22 at 10:21 PM | markets.businessinsider.comBrokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $33.63April 19, 2025 | americanbankingnews.comM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big change. Make America Wealthy Again (M.A.W.A).April 24, 2025 | Paradigm Press (Ad)Leerink Partners Sticks to Its Buy Rating for AnaptysBio (ANAB)April 4, 2025 | markets.businessinsider.comLeerink Partners Sticks to Their Buy Rating for AnaptysBio (ANAB)March 28, 2025 | markets.businessinsider.comAnaptysBio could have positive read from J&J abstracts, says GuggenheimMarch 27, 2025 | markets.businessinsider.comAnaptysBio authorizes $75 million stock buyback planMarch 26, 2025 | investing.comAnaptysBio Announces $75 Mln Stock Repurchase PlanMarch 26, 2025 | nasdaq.comSee More Headlines ANAB Stock Analysis - Frequently Asked Questions How have ANAB shares performed this year? AnaptysBio's stock was trading at $13.24 on January 1st, 2025. Since then, ANAB shares have increased by 52.0% and is now trading at $20.1250. View the best growth stocks for 2025 here. How were AnaptysBio's earnings last quarter? AnaptysBio, Inc. (NASDAQ:ANAB) announced its quarterly earnings results on Thursday, February, 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.61) by $0.89. The biotechnology company earned $43.11 million during the quarter, compared to analysts' expectations of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative trailing twelve-month return on equity of 287.94%. Is AnaptysBio buying back stock? AnaptysBio's Board of Directors authorized a share buyback program on Monday, March 24th 2025, which authorizes the company to buy back $75,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 13.1% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's leadership believes its shares are undervalued. When did AnaptysBio IPO? AnaptysBio (ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are AnaptysBio's major shareholders? AnaptysBio's top institutional investors include Assenagon Asset Management S.A. (0.79%), HighMark Wealth Management LLC (0.30%), Rhumbline Advisers (0.10%) and GAMMA Investing LLC (0.02%). Insiders that own company stock include Ecor1 Capital, Llc, Paul F Lizzul, Eric J Loumeau, Dennis Mulroy, Hollings Renton and Dennis M Fenton. View institutional ownership trends. How do I buy shares of AnaptysBio? Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AnaptysBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that AnaptysBio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Moderna (MRNA) and Alphabet (GOOG). Company Calendar Last Earnings2/27/2025Today4/24/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANAB CIK1370053 Webwww.anaptysbio.com Phone(858) 362-6295FaxN/AEmployees100Year Founded2005Price Target and Rating Average Stock Price Target$33.63 High Stock Price Target$51.00 Low Stock Price Target$20.00 Potential Upside/Downside+64.7%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($5.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-163,620,000.00 Net Margins-289.75% Pretax Margin-289.74% Return on Equity-287.94% Return on Assets-37.25% Debt Debt-to-Equity RatioN/A Current Ratio10.23 Quick Ratio10.23 Sales & Book Value Annual Sales$91.28 million Price / Sales6.86 Cash FlowN/A Price / Cash FlowN/A Book Value$3.32 per share Price / Book6.15Miscellaneous Outstanding Shares30,667,000Free Float20,174,000Market Cap$626.22 million OptionableOptionable Beta-0.09 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ANAB) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredTrump’s treachery Intuitive Surgical at $1.99. Nvidia at $11. Shorting Fannie Mae months before collapse. That’s this analyst’s ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.